FDA schedules advisory meeting to discuss over-the-counter birth control


Shares of Perrigo Co. PRGO, +3.93% gained 2.1% in trading on Monday after the company said a Food and Drug Administration advisory committee meeting has been scheduled to review the application for an over-the-counter birth control. The meeting is set for Nov. 18. The medication, a daily oral contraceptive, is called Opill. If approved, it would be the first OTC birth control pill in the U.S. Perrigo’s stock is up 2.6% this year, while the broader S&P 500 SPX, +1.06% has declined 14.6%.

This article was originally published by Marketwatch.com. Read the original article here.

Previous articleDow Jones Newswires: German inflation resumed upward trend in August
Next articleU.S. stocks gaining ground Monday as investors await August inflation reading


Please enter your comment!
Please enter your name here